ProCE Banner Activity

HIV and the Liver at CROI 2023

Conference Coverage
Clinical Thought

Read my take on studies of HIV/HBV coinfection—including selection of HBV-based ART and hepatocellular carcinoma screening—and considerations for assessing nonalcoholic fatty liver disease in people with HIV.

Released: March 14, 2023

Expiration: March 12, 2024



Gail Matthews

Gail Matthews, MD, PhD, Prof

Program Head, Kirby Institute
University New South Wales
Specialist, Department of Infectious Diseases
St Vincent's Hospital
Sydney, Australia


Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc.

ViiV Healthcare


Prof Gail Matthews, MD, PhD: consultant: AstraZeneca, Janssen; researcher: AbbVie, Gilead Sciences, ViiV Healthcare.